Neutrophil–lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis

JOURNAL ARTICLE published June 2022 in European Journal of Gastroenterology & Hepatology

Authors: Toshifumi Tada | Takashi Kumada | Atsushi Hiraoka | Masashi Hirooka | Kazuya Kariyama | Joji Tani | Masanori Atsukawa | Koichi Takaguchi | Ei Itobayashi | Shinya Fukunishi | Kunihiko Tsuji | Toru Ishikawa | Kazuto Tajiri | Hironori Ochi | Satoshi Yasuda | Hidenori Toyoda | Chikara Ogawa | Takashi Nishimura | Takeshi Hatanaka | Satoru Kakizaki | Noritomo Shimada | Kazuhito Kawata | Takaaki Tanaka | Hideko Ohama | Kazuhiro Nouso | Asahiro Morishita | Akemi Tsutsui | Takuya Nagano | Norio Itokawa | Tomomi Okubo | Taeang Arai | Michitaka Imai | Atsushi Naganuma | Yohei Koizumi | Shinichiro Nakamura | Kouji Joko | Hiroko Iijima | Yoichi Hiasa | On behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group and the Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group